CureVac N.V. (CVAC)
NASDAQ: CVAC · IEX Real-Time Price · USD
+0.015 (0.57%)
At close: Apr 16, 2024, 4:00 PM
-0.035 (-1.31%)
Pre-market: Apr 17, 2024, 4:02 AM EDT

CureVac Statistics

Total Valuation

CureVac has a market cap or net worth of $596.65 million. The enterprise value is $144.43 million.

Market Cap 596.65M
Enterprise Value 144.43M

Important Dates

The next estimated earnings date is Tuesday, May 28, 2024, before market open.

Earnings Date May 28, 2024
Ex-Dividend Date n/a

Share Statistics

CureVac has 223.88 million shares outstanding. The number of shares has increased by 19.43% in one year.

Shares Outstanding 223.88M
Shares Change (YoY) +19.43%
Shares Change (QoQ) +0.01%
Owned by Insiders (%) 45.43%
Owned by Institutions (%) 23.80%
Float 118.65M

Valuation Ratios

PE Ratio n/a
Forward PE 9.17
PS Ratio 13.08
Forward PS 7.12
PB Ratio 0.93
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 3.17
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.56, with a Debt / Equity ratio of 0.07.

Current Ratio 3.56
Quick Ratio 3.17
Debt / Equity 0.07
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -39.57

Financial Efficiency

Return on equity (ROE) is -48.40% and return on invested capital (ROIC) is -47.75%.

Return on Equity (ROE) -48.40%
Return on Assets (ROA) -33.80%
Return on Capital (ROIC) -47.75%
Revenue Per Employee $50,461
Profits Per Employee -$355,745
Employee Count 904
Asset Turnover 0.05
Inventory Turnover 9.67


In the past 12 months, CureVac has paid $71,209 in taxes.

Income Tax 71,209
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -66.44% in the last 52 weeks. The beta is 2.51, so CureVac's price volatility has been higher than the market average.

Beta (1Y) 2.51
52-Week Price Change -66.44%
50-Day Moving Average 3.23
200-Day Moving Average 5.79
Relative Strength Index (RSI) 30.39
Average Volume (30 Days) 774,635

Short Selling Information

The latest short interest is 5.01 million, so 2.24% of the outstanding shares have been sold short.

Short Interest 5.01M
Short Previous Month 4.86M
Short % of Shares Out 2.24%
Short % of Float 4.23%
Short Ratio (days to cover) 6.80

Income Statement

In the last 12 months, CureVac had revenue of $45.62 million and -$321.59 million in losses. Loss per share was -$1.56.

Revenue 45.62M
Gross Profit -114.67M
Operating Income -327.03M
Pretax Income -321.22M
Net Income -321.59M
EBITDA -294.39M
EBIT -313.30M
Loss Per Share -$1.56
Full Income Statement

Balance Sheet

The company has $496.97 million in cash and $44.76 million in debt, giving a net cash position of $452.22 million or $2.02 per share.

Cash & Cash Equivalents 496.97M
Total Debt 44.76M
Net Cash 452.22M
Net Cash Per Share $2.02
Equity / Book Value 640.10M
Book Value Per Share 2.86
Working Capital 410.41M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$290.54 million and capital expenditures -$62.79 million, giving a free cash flow of -$353.33 million.

Operating Cash Flow -290.54M
Capital Expenditures -62.79M
Free Cash Flow -353.33M
FCF Per Share -$1.58
Full Cash Flow Statement


Gross margin is -251.37%, with operating and profit margins of -716.91% and -704.99%.

Gross Margin -251.37%
Operating Margin -716.91%
Pretax Margin -704.16%
Profit Margin -704.99%
EBITDA Margin -645.35%
EBIT Margin -686.81%
FCF Margin -774.56%

Dividends & Yields

CureVac does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -19.43%
Shareholder Yield -19.43%
Earnings Yield -53.90%
FCF Yield -59.22%
Dividend Details

Analyst Forecast

The average price target for CureVac is $15.00, which is 462.85% higher than the current price. The consensus rating is "Hold".

Price Target $15.00
Price Target Difference 462.85%
Analyst Consensus Hold
Analyst Count 4
Revenue Growth Forecast (5Y) 30.94%
EPS Growth Forecast (5Y) -42.39%
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a


CureVac has an Altman Z-Score of -1.61 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -1.61
Piotroski F-Score 2